Category Archives: Medical Research

Review Of Mikhail Blagosklonny’s Illustrative Career

Published / by healthadmin

Mikhail Blagosklonny is a researcher of oncology. He is based in New York, at the Roswell Park Cancer Institute. Mikhail studied at the University of St. Petersburg where he graduated with his Medical Doctorate and Philosophy Degree. He particularly focused on cardiology and experimental medicine. After his studies, he was first appointed at New York Medical College as an associate professor. Afterwards, he joined Ordway Research Institute where he served as a senior scientist until 2009. During the same year, he was appointed to his current position at Roswell Park. Blagosklonny has deep interest in researching about cancer, its treatment, and developing drugs that can protect normal cells in the body. He also researches on aging-related diseases.

Blagosklonny is the chief editor of three widely read journals, which are Cell Cycle, Oncotarget and Aging. In addition, the scientist offers innovative insights to Cell Death and Differentiation where he serves on the editorial board. He has also made significant contributions at Cancer Biology and Therapy where he is an associate editor. Moreover, he has published more than 270 papers in varied journals where he has listed citations that exceed 25,000. Blagosklonny has a wide range of skills relating to Cancer Therapy, Apoptosis, Cancer Cell Biology, Signal Transduction, Protein Kinases, Cell Proliferation, Phosphorylation, and Cell Division among others.

At Cancer Institute of Roswell Park, Mikhail Blagosklonny has used his transformative style of leadership to enhance the growth of the institution. He has managed to expand the methods of cancer prevention, treatment and other anticancer strategies. He has also shared many ideas with other members at the institution, including the different ways of protecting normal cells from electrochemical therapies and special tissue treatment. Additionally, Mikhail has made significant contributions on the right combination of cancer drugs and mechanisms of slowing down the aging of organisms through cancer prevention. Read more on Impact Journals.

Blagosklonny is a well-known researcher who has developed exceptional methods of cancer prevention and treatment. He has extended his research to include the treatment of cancer and aging-related diseases. His publications have been of great help to the company, scientists, readers and the public at large. As a professor of oncology, Mikhail continues to engage in extensive research processes.

Jeanmarie Guenot – Young And Dynamic Entrepreneur In The Biotechnology Industry

Published / by healthadmin

 

JeanMarie Guenot is the President and CEO of Amphivena Therapeutics, according to their website, and is a very popular and influential figure in the biotech industry. She has over 20 years of experience in biotech and pharmaceuticals industry. She did her Masters in Business Administration from the reputed Wharton School of Business, University of Pennsylvania and went on to pursue Ph.D. from the University of California, San Francisco. JeanMarie Guenot started her career as a principal scientist and team leader at Hoffman-La Roche in 1993, where she worked for six years.

 

 

After leaving that job, she moved to Atlas Venture as an Associate in Life Sciences and continued working there for another three years. Having gained considerable experience and knowledge by then in biotechnology and having achieved remarkable success through sincere performance, she joined PDL BioPharma as Vice President of Corporate and Business Development. Jeanmarie continued working at PDL BioPharma for five years, where she understood more closely not just the technical side of the biotech industry, but also the business, management and operational side of it.

 

 

Having a versatile background and experience of working in different stages of a company, such as in venture capital, pharmaceutical R&D, alliance management, corporate and commercial development, project management, supply management, and business development, it won’t be wrong to say that Jeanmarie knows biotech industry like the back of her hand. One of her basic interests in this business is to help rebuild non-profitable companies and build new companies. Amphivena Therapeutics, where she is President and CEO, deals with the development of bifunctional antibody therapies for the treatment of hematologic malignancies.

 

 

Before Amphivena, Jeanmarie founded and ran SKS Ocular, which was a start-up company dealing in ophthalmic therapeutics and treatment. While at PDL Pharmaceuticals, Jeanmarie got extensive experience about the business side of the biotech industry and was responsible for alliance management, venture capital, merger and acquisitions, negotiations, client management, marketing and handled commercial product portfolios.

 

 

In the areas of ophthalmic diseases, cardiovascular diseases, oncology, neurology and autoimmune diseases, Jeanmarie has project, Alliance and portfolio management experience. Her career in the biotechnology industry is an inspiring example for many, especially women who are active in the biotech world and aims to make it big.  Jeanmarie Guenot was instrumental in negotiating a new partnership for Amphivena Therapeutics, which will see them chase the dream of finding a true cure to cancer.